title: Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.
abstract: OBJECTIVE
  This study tested the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse coronary artery disease (CAD) not amenable to any form of mechanical revascularisation.
  
  
  RESULTS
  The study was an open-label, randomised, controlled, blinded end-point classification trial, employing the PROBE (Prospective Open Treatment and Blinded End Point Evaluation) design. A total of 290 patients (mean age 74.6 +/- 9.6 years) with NSTE-AMI and angiographic evidence of severe and diffuse CAD, not amenable to revascularisation by either coronary surgery or angioplasty, were randomised to atorvastatin 80 mg/day (n = 144) or conventional medical treatment (n = 146). A primary end point event (combination of cardiovascular death, non-fatal acute myocardial reinfarction and disabling stroke within 12 months of randomisation) occurred in 16.0% of patients treated with atorvastatin 80 mg/day and in 26.7% of patients receiving conventional treatment (HR 0.56; 95% CI 0.33-0.93, p = 0.027). The study was not blinded. Consequently, a bias in the assessment of clinical outcome cannot be completely excluded.
  
  
  CONCLUSIONS
  In conclusion, when compared with a conventional treatment strategy, full-dose therapy with atorvastatin 80 mg/day provides greater protection against ischaemic recurrences after NSTE-AMI in patients with severe, diffuse, non-revascularisable CAD.
authors.affiliation: Cardiology Division, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy. f.colivicchi@sanfilipponeri.roma.it
authors.forename: Furio
authors.initials: F
authors.lastname: Colivicchi
authors.forename: Marco
authors.initials: M
authors.lastname: Tubaro
authors.forename: David
authors.initials: D
authors.lastname: Mocini
authors.forename: Alberto
authors.initials: A
authors.lastname: Genovesi Ebert
authors.forename: Stefano
authors.initials: S
authors.lastname: Strano
authors.forename: Giovanni
authors.initials: G
authors.lastname: Melina
authors.forename: Massimo
authors.initials: M
authors.lastname: Uguccioni
authors.forename: Massimo
authors.initials: M
authors.lastname: Santini
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000069059:Atorvastatin; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007558:Italy; D008297:Male; D009203:Myocardial Infarction; D017202:Myocardial Ischemia / Q000517:prevention & control; D011758:Pyrroles / Q000008:administration & dosage* / Q000494:pharmacology; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin